ClinicalTrials.gg
CompletedNCT02670044Updated Jan 3, 2022

A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

A Phase 1 interventional study of Cobimetinib and Idasanutlin in Leukemia, Myeloid, Acute, sponsored by Hoffmann-La Roche. Completed at 17 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-03.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Leukemia, Myeloid, Acute by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Leukemia, Myeloid, Acute · Hoffmann-La Roche.

Enrollment
3rd of 12
88 · median 42
Started
2016
with 1 other
Phase 1
9 of 12
none open now
Registered
6th of 12
by date

Among the 12 studies in Leukemia, Myeloid, Acute by Hoffmann-La Roche, this one is the 3rd largest by enrollment, is one of 2 that started in 2016, is one of 9 in phase 1, and was the 6th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

None of the 12 studies in Leukemia, Myeloid, Acute by Hoffmann-La Roche is open now. The open studies under Leukemia, Myeloid, Acute, anywhere →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Leukemia, Myeloid, Acute by Hoffmann-La Roche as a file.
02

Study summary

The primary objective for this study is to assess the safety and tolerability as well as preliminary efficacy of venetoclax in combination with cobimetinib, and venetoclax in combination with idasanutlin in patients with relapsed or refractory acute myeloid leukemia (R/R) AML who are not eligible for cytotoxic therapy.

03

Conditions studied

  • Leukemia, Myeloid, Acute
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological confirmation of AML after prior anti-leukemic therapy by WHO classification
  • Ineligible for cytotoxic therapy defined by the following:

    a. Age (>/=) 75 years or b. age 18- 74 years with at least one of the following comorbidities: i. (ECOG) Performance Status of 2 or 3 ii. Cardiac history of congestive heart failure requiring treatment or (\</=) 50% or chronic stable angina iii. Diffusing capacity of the lungs for carbon monoxide (\</=) 65% or of expiration (\</=) 65% iv. (>/=) 30 mL/min to\< 45 mL/min v. any other comorbidity that the physician judges to be incompatible with intensive chemotherapy must be reviewed and approved by the Medical Monitor before screening and study enrollment.

  • of at least 12 weeks
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
  • Adequate liver and renal function

Exclusion criteria

Exclusion Criteria:

  • Patients with acute promyelocytic leukemia (French-American-British [FAB] class M3 AML)
  • Known active central nervous system (CNS) involvement with AML at study entry
  • Performance Status (>/=) 3 in patients who are (>/=) 75 years old or ECOG Performance Status of 4, regardless of age
  • Prior exposure to Bcl-2 inhibitors, murine double minute 2 (MDM2) antagonists or prior exposure to experimental treatment targeting Raf, mitogen-activated protein kinase (MEK), or the mitogen-activated protein kinase (MAPK) RAS/RAF/MEK/ERK MAPK pathway
  • Positive for virus (HCV), surface antigen (HBsAg) and known history of , , active infection and cardiovascular diseases (CVs)
  • Received strong cytochrome (CYP) 3A inhibitors, moderate inhibitors, strong CYP3A inducers and moderate CYP3A inducers within 7 days prior to initiation of study treatment
  • History of symptomatic Clostridium difficile infection within 1 month prior to dosing

Additional arm specific exclusion criteria:

Dose Escalation Arm A (Venetoclax and Cobimetinib):

  • History or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment/central serous chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular degeneration
  • (LVEF) below institutional lower limit of normal (LLN) or below 50%, whichever is lower

Arm B (Venetoclax and Idasanutlin):

  • Received the following within 7 days prior to the initiation of study treatment: Strong CYP2C8 inhibitors or CYP2C8 substrates, OATP1B1/3 substrates
  • Received the following within 14 days prior to the initiation of study treatment: Strong CYP2C8 inducers
  • History of liver cirrhosis by radiologic, clinical or laboratory data, or despite normal liver function tests
  • Received treatment with oral or parenteral anticoagulants/anti- agents within 7 days prior to initiation of study treatment.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Dose Escalation: Arm A (Venetoclax 400mg + Cobi 40mg)

    Participants received Venetoclax 400mg daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib 40mg daily on Days 1-21 of each 28-day treatment cycle.

    Drug: Cobimetinib · Drug: Venetoclax

  • Experimental
    Dose Escalation: Arm A (Venetoclax 600mg + Cobi 40mg)

    Participants received Venetoclax 600mg daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib 40mg daily on Days 1-21 of each 28-day treatment cycle.

    Drug: Cobimetinib · Drug: Venetoclax

  • Experimental
    Dose Escalation: Arm A (Venetoclax 800mg + Cobi 40mg)

    Participants received Venetoclax 800mg daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib 40mg daily on Days 1-21 of each 28-day treatment cycle.

    Drug: Cobimetinib · Drug: Venetoclax

  • Experimental
    Dose Escalation: Arm A (Venetoclax 400mg + Cobi 60mg)

    Participants received Venetoclax 400mg daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib 60mg daily on Days 1-21 of each 28-day treatment cycle.

    Drug: Cobimetinib · Drug: Venetoclax

  • Experimental
    Dose Escalation: Arm B (Venetoclax 400mg + Ida 200mg)

    Participants received Venetoclax 400mg daily on Days 1-28 of each 28 day treatment cycle and Idasanutlin 200mg daily or twice daily on Days 1-5 of each 28 day treatment cycle.

    Drug: Idasanutlin · Drug: Venetoclax

  • Experimental
    Dose Escalation: Arm B (Venetoclax 600mg + Ida 150mg)

    Participants received Venetoclax 600mg daily on Days 1-28 of each 28 day treatment cycle and Idasanutlin 150mg daily or twice daily on Days 1-5 of each 28 day treatment cycle.

    Drug: Idasanutlin · Drug: Venetoclax

  • Experimental
    Dose Escalation: Arm B (Venetoclax 600mg + Ida 200mg)

    Participants received Venetoclax 600mg daily on Days 1-28 of each 28 day treatment cycle and Idasanutlin 200mg daily or twice daily on Days 1-5 of each 28 day treatment cycle.

    Drug: Idasanutlin · Drug: Venetoclax

  • Experimental
    Dose Escalation: Arm B (Venetoclax 400mg + Ida 400mg)

    Participants received Venetoclax 400mg daily on Days 1-28 of each 28 day treatment cycle and Idasanutlin 400mg daily or twice daily on Days 1-5 of each 28 day treatment cycle.

    Drug: Idasanutlin · Drug: Venetoclax

  • Experimental
    Dose Optimisation: Arm B (Ven 600mg (Day 1 to 21) + Ida 150mg)

    Participants received Venetoclax 600mg daily on Days 1-21 of each 28 day treatment cycle and Idasanutlin 150mg daily on Days 1-5 of each 28 day treatment cycle.

    Drug: Idasanutlin · Drug: Venetoclax

Interventions

  • Cobimetinib will be administered orally as per schedule in Arm description.

  • Idasanutlin will be administered orally as per schedule in Arm description.

  • Venetoclax will be administered orally as per schedule in Arm description.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose Limiting Toxicities (DLTs)

    Time frame: From Cycle 1 Day 1 to Cycle 2 Day 1 for a minimum of 28 days

  2. Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)

    Time frame: Baseline up until 30 days after the last dose of study drug (up to a maximum of 4 years, 9 months)

Secondary outcomes

  1. Overall Response Rate (ORR) (Complete Remission (CR) + Complete Remission with Incomplete Blood Recovery (CRi) + Incomplete Platelet Count Recovery (CRp) + Partial Remission/Partial Response [PR])

    Time frame: Up to 2 years

  2. Complete Remission/complete response (CR) + Complete Remission with Incomplete Blood Recovery (CRi) + Incomplete Platelet Count Recovery (CRp)

    Time frame: Up to 2 years

  3. CR + Complete Remission with Partial Hematologic Recovery (CRh) Rate

    Time frame: Up to 2 years

  4. Duration of Response (DOR)

    Time frame: Up to 2 years

  5. Time to Progression (TTP)

    Time frame: Up to 2 years

  6. Progression-Free Survival (PFS)

    Time frame: Up to 2 years

  7. Event-Free Survival (EFS)

    Time frame: Up to 2 years

  8. Leukemia-Free Survival (LFS)

    Time frame: Up to 2 years

  9. Overall Survival (OS)

    Time frame: Up to 2 years

  10. Pharmacokinetics of Venetoclax Area Under the Concentration-Time Curve from Time Zero to Last Measurable Concentration (AUC0-24hr)

    Time frame: Up to 6 months

  11. Pharmacokinetics of Venetoclax Maximum Observed Concentration (Cmax)

    Time frame: Up to 6 months

  12. Pharmacokinetics of Cobimetinib Area Under the Concentration-Time Curve from Time Zero to Last Measurable Concentration (AUC0-24hr)

    Time frame: Up to 6 months

  13. Pharmacokinetics of Cobimetinib Maximum Observed Concentration (Cmax)

    Time frame: Up to 6 months

  14. Pharmacokinetics of Idasanutlin Area Under the Concentration-Time Curve from Time Zero to Last Measurable Concentration (AUC0-24hr)

    Time frame: Up to 6 months

  15. Pharmacokinetics of Idasanutlin Maximum Observed Concentration (Cmax)

    Time frame: Up to 6 months

  16. Number of Participants Reporting Symptoms in Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Questionnaire

    Time frame: Up to 2 years

  17. Rate of Transfusion Independence

    Time frame: Up to 2 years

  18. Duration Of Transfusion Independence, Defined As The Number Of Consecutive Days Of Transfusion Independence, Measured From 1 Day After Last Transfusion To Disease Progression Or Subsequent Transfusion

    Time frame: Up to 2 years

  19. Minimal Residual Disease (MRD) In The Bone Marrow To Evaluate The Depth Of Response

    Time frame: Up to 2 years

07

Study locations

17 sites
  • USC Norris Cancer Center
    Los Angeles, California 90033, United States
  • UC Davis; Comprehensive Cancer Center
    Sacramento, California 95817, United States
  • Univ of Calif, San Francisco
    San Francisco, California 94143, United States
  • University of Colorado
    Aurora, Colorado 80045-2517, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Alberta Hospital
    Edmonton, Alberta T6G 1Z1, Canada
  • Princess Margaret Cancer Center
    Toronto, Ontario M5G 1Z5, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Hopital Avicenne, Paris
    Bobigny, 93009, France
  • Institut Paoli Calmettes
    Marseille, 13009, France
  • CHU de Bordeaux
    Pessac, 33600, France
  • University of Bologna
    Bologna, Emilia-Romagna 40126, Italy
  • Presidio san salvatore muraglia
    Pesaro, Emilia-Romagna 61122, Italy
  • Universita di Roma
    Roma, Emilia-Romagna 100, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Dec 2020, 57 months.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's 57 months is above that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2016
First posted
Feb 1, 2016
StartActual
Mar 9, 2016
Primary completionActual
Dec 10, 2020
CompletionActual
Dec 10, 2020
Last update
Jan 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02670044
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 1, 2016
Start date
Mar 9, 2016
Primary completion
Dec 10, 2020
Completion
Dec 10, 2020
Last update
Jan 3, 2022

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cobimetinib · RG7388

Start the discussion